Antibody levels towards Epstein Barr virus antigens and molecular mimics in multiple sclerosis patients and controls
Citation and access
Citation and access
Data access level:
Creator/Principal investigator(s):
Research principal:
Data contains personal data:
Yes
Type of personal data:
Genetic data (only two alleles), Year of birth, sex, Age at sampling. Antibody levels, could with data stored locally be used to identify persons
Sensitive personal data:
Yes
Citation:
Language:
Method and outcome
Method and outcome
Unit of analysis:
Population:
Patients with multiple sclerosis in Sweden who have given their consent to participate in the EIMS study and population-based controls. We have analyzed plasma from blood samples from these individuals for levels of antibodies directed against the Epstein Barr Virus antigen as well as human proteins with amino acid homologies to the EBNA1 protein
Time method:
Study design:
- Observational study
- Case-control study
Description of study design:
Newly diagnosed MS patients were invited to participate in the study, which consisted of answering a questionnaire and providing a blood sample. Age, gender and region matched controls have been invited to participate in the study, they have also answered a questionnaire and provided blood samples.
Description of sampling:
Newly diagnosed MS patients identified via neurology clinics in Sweden were invited to participate in the study, which consisted of answering a questionnaire and providing a blood sample. Age, gender and region matched controls have been invited to participate in the study, they have also answered a questionnaire and provided blood samples.
Time period(s) investigated:
Variables:
33
Number of individuals/objects:
1311
Data format/data structure:
Samples/material - Existing from scientific collection/biobank
Samples/material - Existing from scientific collection/biobank
Name:
Type(s) of sample:
Geographic coverage
Geographic coverage
Geographic location:
Geographic description:
whole of Sweden
Administrative information
Administrative information
Responsible department/unit:
Department of Clinical Neuroscience [K8]
Ethics Review:
Swedish Ethical Review Authority - 2019-00639
Funding
Funding
Funding agency:
- Swedish Research Council
Opens a new window at ror.org.
ROROpens in a new tab
Award number:
2022-00565_VR
Award title:
Causes and pathogenesis of multiple sclerosis; prevention and precise treatment
Funding information:
In MS, immune cells from the blood enter the central nervous system causing damage to nerve tracts. With time, MS becomes progressive with increased disabilities. Some therapies can dampen the relapse rates up to 90%, but act broadly on immunity, which can lead to severe complications. Since MS is due to inflammation, the disease should be curable. We study the causes, pathogenesis and severity/progression of MS in large-scale clinical MS materials, integrated with molecular genetics/immunology and studies in rodent models, to achieve prevention and precise treatment. The current project focus on function of factors we have found to be strongly associated to disease, and thereby deemed relevant and often unique for MS, providing a basis for precision medicine. We aim to: 1) Further define, lifestyle/environmental factors and pathways that drive MS risk and severity/progression. 2) Decipher gene-environment interactions, and interactions between environmental factors. 3) Define the function of selected MS gene loci and environmental factors. 4) Define disease relevant T cells, and explore precise tolerance therapies; first in rodent MS models, in which the detailed knowledge of auto-antigenic targets have enabled precise therapies and cure. Translation to human MS is expected. 5) Develop MS biomarkers in blood samples for diagnosis, severity, prognosis and disease heterogeneity. We approach these aims in ten different, but strongly inter-related sub-projects.
